Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
株式のランク #26668
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
株価
$5.54
最終同期: 2024-09-18
時価総額
$38.76M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Alimera Sciences, Inc. (ALIM)

カテゴリー

Alimera Sciences, Inc.(ALIM)のP/B比率
August 2026 時点のP/B比率 TTM: 3.07
Alimera Sciences, Inc. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 3.07 です。2022 年末時点でのP/B比率は -0.91 でした。
Alimera Sciences, Inc. の P/B 比率の履歴(2006 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
2026 (TTM) 3.07 28.33%
2023 2.39 -362.98%
2022 -0.91 -93.00%
2021 -12.99 379.74%
2020 -2.71 -66.72%
2019 -8.13 -135.04%
2018 23.22 288.76%
2017 5.97 167.96%
2016 2.23 -45.46%
2015 4.09 -9.57%
2014 4.52 -115.00%
2013 -30.13 -2,488.44%
2012 1.26 -19.62%
2011 1.57 -78.14%
2010 7.18 -331.53%
2009 -3.10 1,917.76%
2008 -0.15 -58.80%
2007 -0.37 -21.65%
2006 -0.48 0.00%